Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Russia's 36.6 makes appointments

This article was originally published in Scrip

Executive Summary

One of Russia's largest pharmacy chains, The Pharmacy Chain 36.6, has made several appointments. Ruslan Vorobel has joined from the Metro group to become the company's commercial director. Andrey Atemasov has been appointed head of its marketing department; he previously worked for various firms including Williams-Sonoma and Redenvelope. Marina Ivanova has moved from the Russian supermarket chain Perekrestok to become The Pharmacy Chain 36.6's director of human resources. Alexey Skrypnikov, who was previously executive director of another local pharmacy chain, Stariy Lekar, has been appointed head of The Pharmacy Chain 36.6's business unit for Moscow and central Russia. Cyril Ivanov has become director of operations in the regions, Alexandra Kozhaeva director of procurement, and the responsibilities of Dmitriy Godunov, The Pharmacy Chain 36.6's first deputy director general, have been expanded to cover logistics control across Russia.

You may also be interested in...



Poland's new law fixes prices and trade mark-ups of reimbursed drugs

Poland's president, Bronislaw Komorowski, has signed a reimbursement bill into the law which will come into force on 1 January.

Global pharma boosts business in Russia - Why Russia (introduction)

In the past two years, most multinational pharmaceutical companies announced plans to create production facilities in Russia. They had been ignoring such an opportunity for years, and there were reasons for that. They included risks to investments, administrative barriers, unclear regulations assuming various interpretations and corruption.

Russia's president Medvedev wants talks on trials mutual recognition with US and EU

Russia's president Dmitriy Medvedev has requested that his government start talks with the US and the EU on the mutual recognition of clinical trial results (including paediatric trials) and prepare proposals for corresponding amendments of existing regulations.

UsernamePublicRestriction

Register

OM005385

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel